AstraZeneca Gilead Merger Intriguing But Unlikely
Bloomberg Rumor Causes A Stir
The possible creation of a pharma giant worth around $230bn of two firms who are leading the industry’s efforts to combat COVID-19 has caught the imagination but the likelihood of a match is limited.
You may also be interested in...
AstraZeneca’s half-year results, out on 30 July, will be keenly watched due to the pharma’s attractive near-term growth, pipeline catalysts and its promising COVID-19 vaccine.
The German pharma’s top business development execs explain how they balance IO and targeted cancer therapy in their portfolio, views on major M&A and how to make deals during a global pandemic.
Clover enters the clinical trial stage in race to develop a vaccine, while the UK moves to protect a range of key industries from foreign takeover, including vaccines manufacturers. Meanwhile, confirmed cases in Beijing continue to rise.